Diagnostics company NanoLogix (OTCBB:NNLX) is preparing several U.S. Food and Drug Administration applications for its rapid bacteria-testing technology.
NanoLogix said the applications will include results of tests that examined the company’s technology in detecting tuberculosis and Group B Streptococcus, according to a statement from the Hubbard, Ohio-based company.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The company’s technology involves a proprietary water-permeable cellulose membrane that’s surrounded by a nutrient mix and lays in a petri dish.
Bacteria grows on the membrane, which is then transferred to a staining plate, and allows bacterial microcolonies to become visible more quickly than competing technologies, according to the company.
NanoLogix is working with an unidentified company that will submit the applications to the FDA. “While it takes the time line out of our hands, it frees NanoLogix staff and resources to focus on further research and development of our technologies,” CEO Bret Barnhizer said.
Separately, NanoLogix said it’s developing an antibody for Listeria for use in prescreening food packaging, food processing equipment and preparation surfaces.
